Animal Models of T Cell-Mediated Skin Diseases

Nevertheless, attrition rates in clinical development are still very high, and up to 90% of new compounds fail in clinical phase I - III trials, which is partially due to lack of clinical efficacy. Such animal models should have impact not only on inflammatory dermatoses but also on other inflammatory disorders due to their model character.